Primary source: Cancellation of Notified Cosmetic Products
Issuance of non-compliance notifications for specific vaccine lots, including dates for COMIRNATY and MENACTRA. Notably, the compliance notifications detail issues impacting distribution.
This update is critical for regulatory compliance and safety management of vaccine products. Non-compliance could affect public health outcomes and regulatory obligations.
Implement an immediate review of affected vaccine lots and ensure all relevant stakeholders are informed of the compliance issues for Signal Management processes.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Implement an immediate review of affected vaccine lots and ensure all relevant stakeholders are informed of the compliance issues for Signal Management processes.
The National Pharmaceutical Regulatory Agency (NPRA) of Malaysia has issued notifications regarding non-compliance for various vaccine lots including COMIRNATY and MENACTRA. This affects the release and usage of these products.
What changed: Issuance of non-compliance notifications for specific vaccine lots, including dates for COMIRNATY and MENACTRA. Notably, the compliance notifications detail issues impacting distribution.
Why it matters: This update is critical for regulatory compliance and safety management of vaccine products. Non-compliance could affect public health outcomes and regulatory obligations.
Practical implication: Implement an immediate review of affected vaccine lots and ensure all relevant stakeholders are informed of the compliance issues for Signal Management processes.
Published from the regulator source ingestion pipeline after PV impact triage.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
